174 related articles for article (PubMed ID: 12827272)
1. Antisense-mediated redirection of mRNA splicing.
Vacek M; Sazani P; Kole R
Cell Mol Life Sci; 2003 May; 60(5):825-33. PubMed ID: 12827272
[TBL] [Abstract][Full Text] [Related]
2. [The application of antisense technology in ophthalmology].
Guo Y; Ge J
Yan Ke Xue Bao; 1998 Jun; 14(2):108-15. PubMed ID: 12580046
[TBL] [Abstract][Full Text] [Related]
3. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides.
Sierakowska H; Sambade MJ; Agrawal S; Kole R
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):12840-4. PubMed ID: 8917506
[TBL] [Abstract][Full Text] [Related]
4. Making antisense of splicing.
Garcia-Blanco MA
Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
[TBL] [Abstract][Full Text] [Related]
5. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.
Sazani P; Kole R
J Clin Invest; 2003 Aug; 112(4):481-6. PubMed ID: 12925686
[TBL] [Abstract][Full Text] [Related]
7. Translational development of splice-modifying antisense oligomers.
Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of pre-mRNA splicing by antisense RNA in vitro: effect of RNA containing sequences complementary to exons.
Volloch V; Schweitzer B; Rits S
Biochem Biophys Res Commun; 1991 Sep; 179(3):1593-9. PubMed ID: 1656959
[TBL] [Abstract][Full Text] [Related]
9. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
[TBL] [Abstract][Full Text] [Related]
10. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
11. Exon-skipping advances for Duchenne muscular dystrophy.
Echevarría L; Aupy P; Goyenvalle A
Hum Mol Genet; 2018 Aug; 27(R2):R163-R172. PubMed ID: 29771317
[TBL] [Abstract][Full Text] [Related]
12. Splicing intervention for Duchenne muscular dystrophy.
McClorey G; Fletcher S; Wilton S
Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
[TBL] [Abstract][Full Text] [Related]
13. Screening for antisense modulation of dystrophin pre-mRNA splicing.
Dickson G; Hill V; Graham IR
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S67-70. PubMed ID: 12206799
[TBL] [Abstract][Full Text] [Related]
14. Progress toward therapy with antisense-mediated splicing modulation.
Du L; Gatti RA
Curr Opin Mol Ther; 2009 Apr; 11(2):116-23. PubMed ID: 19330717
[TBL] [Abstract][Full Text] [Related]
15. Antisense strategies: functions and applications in immunology.
Varga LV; Tóth S; Novák I; Falus A
Immunol Lett; 1999 Aug; 69(2):217-24. PubMed ID: 10482355
[TBL] [Abstract][Full Text] [Related]
16. Short-term and long-term modulation of gene expression by antisense therapeutics.
Sazani P; Vacek MM; Kole R
Curr Opin Biotechnol; 2002 Oct; 13(5):468-72. PubMed ID: 12459339
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases.
Du L; Gatti RA
J Immunol Methods; 2011 Feb; 365(1-2):1-7. PubMed ID: 21147113
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.
Aartsma-Rus A; Janson AA; Heemskerk JA; De Winter CL; Van Ommen GJ; Van Deutekom JC
Ann N Y Acad Sci; 2006 Oct; 1082():74-6. PubMed ID: 17145928
[TBL] [Abstract][Full Text] [Related]
19. Antisense strategies for the control of aberrant gene expression.
Sczakiel G
J Hematother; 1994; 3(4):305-13. PubMed ID: 7735826
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake.
Schmajuk G; Sierakowska H; Kole R
J Biol Chem; 1999 Jul; 274(31):21783-9. PubMed ID: 10419493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
